H. Courtney Hodges, PhD

Revealing novel SMARCA4-related dependencies in mixed-lineage leukemia

Mixed-lineage leukemia (MLL) is an aggressive blood cancer affecting ~ 5,000 infants in the U.S. each year. Unlike other types of childhood leukemia, MLL has few treatment options and a five-year survival rate of only 40%. Through our studies, we will identify and validate entirely new precision approaches for treating MLL.